Literature DB >> 12952836

Matrix metalloproteinases as novel disease markers in Takayasu arteritis.

Akifumi Matsuyama1, Naohiko Sakai, Masato Ishigami, Hisatoyo Hiraoka, Susumu Kashine, Ayumu Hirata, Tadashi Nakamura, Shizuya Yamashita, Yuji Matsuzawa.   

Abstract

BACKGROUND: Takayasu arteritis (TA) is a chronic vasculitis that primarily affects large elastic arteries. Monitoring of disease activity is crucial because the disease tends to progress despite treatment with glucocorticoid and/or immunosuppressive agents. Erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) have generally been used as disease activity markers, but these are nonspecific inflammatory markers and lack the sensitivity and specificity to accurately monitor the disease status. Given the histological findings characterized by destruction of elastic fibers, we hypothesized that matrix metalloproteinases (MMPs) could be useful as markers of disease activity in TA. METHODS AND
RESULTS: A consecutive series of 25 patients with TA were enrolled in this study. According to the National Institutes of Health criteria of disease activity, 11 were in an active phase and the remaining 14 were in remission. Circulating levels of MMP-2, MMP-3, and MMP-9 were determined by ELISA in all patients with TA and controls. MMP-2 levels were higher in patients with TA than in controls, but no correlation was found between serum MMP-2 and disease activity score. In contrast, MMP-3 and MMP-9 levels in patients with active disease were higher than in patients in remission and controls, and a positive correlation was demonstrated between circulating levels of MMP-3 or MMP-9 and disease activity score. The high levels of MMP-3 and MMP-9 improved when patients underwent remission.
CONCLUSIONS: The present results indicate that MMP-2 can be helpful in diagnosing TA and that MMP-3 and MMP-9 can be used as activity markers for TA.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12952836     DOI: 10.1161/01.CIR.0000090689.69973.B1

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  34 in total

1.  Accelerated atherosclerosis in patients with Wegener's granulomatosis.

Authors:  K de Leeuw; J-S Sanders; C Stegeman; A Smit; C G Kallenberg; M Bijl
Journal:  Ann Rheum Dis       Date:  2004-09-16       Impact factor: 19.103

2.  Circulating markers of vascular injury and angiogenesis in antineutrophil cytoplasmic antibody-associated vasculitis.

Authors:  Paul A Monach; Gunnar Tomasson; Ulrich Specks; John H Stone; David Cuthbertson; Jeffrey Krischer; Linna Ding; Fernando C Fervenza; Barri J Fessler; Gary S Hoffman; David Ikle; Cees G M Kallenberg; Carol A Langford; Mark Mueller; Philip Seo; E William St Clair; Robert Spiera; Nadia Tchao; Steven R Ytterberg; Yi-Zhong Gu; Ronald D Snyder; Peter A Merkel
Journal:  Arthritis Rheum       Date:  2011-12

Review 3.  Takayasu's arteritis: a review of the literature.

Authors:  Silvia Maffei; Michela Di Renzo; Giovanni Bova; Alberto Auteri; Anna Laura Pasqui
Journal:  Intern Emerg Med       Date:  2006       Impact factor: 3.397

4.  Altered plasma matrix metalloproteinase-9/tissue inhibitor of matrix [corrected] metalloproteinase-1 concentration during the early postoperative period in patients with colorectal cancer.

Authors:  I Kirman; S Jain; V Cekic; A Belizon; E Balik; P Sylla; T Arnell; K A Forde; R L Whelan
Journal:  Surg Endosc       Date:  2006-01-21       Impact factor: 4.584

Review 5.  Aortitis.

Authors:  Heather L Gornik; Mark A Creager
Journal:  Circulation       Date:  2008-06-10       Impact factor: 29.690

6.  The Asia Pacific meeting on vasculitis and ANCA 2012 workshop on Takayasu arteritis: advances in diagnosis and medical treatment.

Authors:  Mitsuaki Isobe
Journal:  Clin Exp Nephrol       Date:  2013-09-26       Impact factor: 2.801

Review 7.  New insights on biomarkers in systemic vasculitis.

Authors:  Rodolfo Perez-Alamino; Hernán Maldonado-Ficco
Journal:  Curr Rheumatol Rep       Date:  2015-03       Impact factor: 4.592

8.  Development of outcome measures for large-vessel vasculitis for use in clinical trials: opportunities, challenges, and research agenda.

Authors:  Haner Direskeneli; Sibel Z Aydin; Tanaz A Kermani; Eric L Matteson; Maarten Boers; Karen Herlyn; Raashid A Luqmani; Tuhina Neogi; Philip Seo; Ravi Suppiah; Gunnar Tomasson; Peter A Merkel
Journal:  J Rheumatol       Date:  2011-07       Impact factor: 4.666

9.  Risk factors for cardiovascular disease and endothelin-1 levels in Takayasu arteritis patients.

Authors:  Alexandre Wagner Silva de Souza; Henrique Ataíde Mariz; Edgard Torres Reis Neto; Anne Elizabeth Diniz Arraes; Neusa Pereira da Silva; Emília Inoue Sato
Journal:  Clin Rheumatol       Date:  2008-12-05       Impact factor: 2.980

Review 10.  Large vessel vasculitis.

Authors:  Ashima Gulati; Arvind Bagga
Journal:  Pediatr Nephrol       Date:  2009-10-17       Impact factor: 3.714

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.